Stock comparison
BrainsWay
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 75B | IDXX |
| Benjamin Graham | 70D | 80A | IDXX |
| Philip Fisher | 57C | 75B | IDXX |
| Peter Lynch | 52C | 71B | IDXX |
| Joel Greenblatt | 46D | 83C | IDXX |
| Charlie Munger | 41D | 87A | IDXX |
| Terry Smith | 52D | 84A | IDXX |
Side-by-side metrics
| Metric | BWAY | IDXX |
|---|---|---|
| Market cap | $592.27M | $44.12B |
| P/E (TTM) | 75.0x | 39.0x |
| EV/EBIT | 123.9x | 31.6x |
| ROIC (TTM) | 5.05% | 40.66% |
| Gross margin | 75.42% | 62.05% |
| Net margin | 13.5% | 24.63% |
| Revenue CAGR 5y | 15.42% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
- Debt / Equity0.1xvs 0.7x+87%
- Revenue CAGR 5y15.42%vs 7.56%+51%
- Gross margin75.42%vs 62.05%+18%
IDXX leads on
- Market cap$44.12Bvs $592.27M+99%
- ROIC (TTM)40.66%vs 5.05%+88%
- EV/EBIT31.6xvs 123.9x+74%
- P/E (TTM)39.0xvs 75.0x+48%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.